Randomised clinical trial: Rabeprazole improves symptoms in patients with functional dyspepsia in Japan

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 729-740

  Iwakiri, R ^a   Tominaga, K ^b   Furuta, K ^c   Inamori, M ^d   Furuta, T ^e   Masuyama, H ^f   Kanke, K ^g   Nagahara, A ^h   Haruma, K ⁱ   Kinoshita, Y ^c   Higuchi, K ^j   Takahashi, S ^k   Kusano, M ^l   Iwakiri, K ^m   Kato, M ⁿ   Hongo, M ^o   Hiraishi, H ^g   Watanabe, S ^h   Miwa, H ^p   Naito, Y ^q   Fujimoto, K ^a   Arakawa, T ^b   more..

^a SAGA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Masuyama Gastrointestinal Clinic   (Japan)

^g DOKKYO MEDICAL UNIVERSITY   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KAWASAKI MEDICAL SCHOOL   (Japan)

^j OSAKA MEDICAL COLLEGE   (Japan)

^k KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l GUNMA UNIVERSITY HOSPITAL   (Japan)

^m NIPPON MEDICAL SCHOOL   (Japan)

ⁿ HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^o TOHOKU UNIVERSITY HOSPITAL   (Japan)

^p HYOGO COLLEGE OF MEDICINE   (Japan)

^q KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RABEPRAZOLE;

ADULT; ADVERSE OUTCOME; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; EPIGASTRIC BURNING; EPIGASTRIC PAIN; FEMALE; GASTROENTERITIS; HELICOBACTER PYLORI; HUMAN; HYPERTRIGLYCERIDEMIA; JAPAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SATIETY; STOMATITIS; SYMPTOM; TREATMENT DURATION;

DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RABEPRAZOLE; TREATMENT OUTCOME;

EID: 84883480159     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12444     Document Type: Article

References (28)

1. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN,. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42
2. Aro P, Talley NJ, Agréus L, et al,. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther 2011; 33: 1215-24.
3. Tack J, Kindt S,. Pathogenesis and therapy for idiopathic dyspepsia. Curr Gastroenterol Rep 2005; 7: 437-44.
4. Sarnelli G, Vandenberghe J, Tack J,. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig Liver Dis 2004; 36: 371-6.
5. Nyrén O, Adami HO, Gustavsson S, Lindgren PG, Lööf L, Nyberg A,. The epigastric distress syndrome. A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia. J Clin Gastroenterol 1987; 9: 303-9.
6. Moayyedi P, Soo S, Deeks J, et al,. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003; 17: 1215-27.
7. Sakurai K, Nagahara A, Inoue K, et al,. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol 2012; 12: 42.
8. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al,. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100: 1477-88.
9. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR,. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47: 473-80.
10. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ,. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004; 116: 740-8.
11. van Zanten SV, Armstrong D, Chiba N, et al,. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol 2006; 101: 2096-106.
12. Talley NJ, Meineche-Schmidt V, Paré P, et al,. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
13. Kinoshita Y, Hongo M,; Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol 2012; 107: 522-30.
14. Kinoshita Y, Ashida K, Hongo M,; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33: 213-24.
15. Hayato S, Hasegawa S, Hojo S, et al,. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol 2012; 68: 579-88.
16. Tack J, Talley NJ, Camilleri M, et al,. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
17. Thompson WG, Drossman DA, Talley NJ, et al,. Rome III Diagnostic Questionnaire for the Adult Functional GI disorders (including Alram Question) and Scoring Algorism. In:, Drossman DA, ed. ROME III. The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates, Inc, 2006; 917-51.
18. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al,. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther 2006; 23: 521-9.
19. Kusano M, Shimoyama Y, Sugimoto S, et al,. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39: 888-91.
20. Wong WM, Wong BC, Hung WK, et al,. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
21. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ,. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329-37.
22. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T,. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
23. Iijima K, Ohara S, Koike T, Sekine H, Shimosegawa T,. Gastric acid secretion of normal Japanese subjects in relation to Helicobacter pylori infection, aging, and gender. Scand J Gastroenterol 2004; 39: 709-16.
24. Sanaka M, Yamamoto T, Kuyama Y,. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 2010; 55: 2431-40.
25. Tosetti C, Stanghellini V, Tucci A, et al,. Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. Dig Dis Sci 2000; 45: 252-7.
26. Kerrigan DD, Mangnall YF, Read NW, Johnson AG,. Influence of acid-pepsin secretion on gastric emptying of solids in humans: studies with cimetidine. Gut 1991; 32: 1295-7.
27. Miwa H, Nakajima K, Yamaguchi K, et al,. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther 2007; 26: 257-64.
28. Miwa H, Ghoshal UC, Fock KM, et al,. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol 2012; 27: 626-41.